A Scottish company at the forefront of genetic medical research has been awarded a £1.9 grant to expand its programme of cell and gene therapy. Synpromics Ltd, based in Roslin, is pioneering research that could unlock a one treatment cure for diseases such as leukaemia and certain types of blindness. The Scottish Enterprise research and development (R&D) grant will enable the firm to invest a...
A spinout company whose technology could save the lives of thousands of dialysis patients has secured £500,000 from Mercia Fund Managers, in the first investment deal since Mercia’s partnership with the University of Edinburgh was announced in November 2017. Invizius stems from years of research by biologist Dr Andy Herbert and his team, who believe they have found a way to reduce the risk of cardiovascular disease...
Dundee based, Cyclacel Pharmaceuticals, Inc. a biopharmaceutical company developing oral therapies that target various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced the presentation by investigators led by William Plunkett, PhD, Professor and Deputy Chair, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, of preclinical data demonstrating strong synergy between Cyclacel’s CDK2/9 inhibitor, CYC065, and ...
Nearly 80 genes that could be linked to depression have been discovered by scientists. The findings could help explain why some people may be at a higher risk of developing the condition, researchers say. The study could also help researchers develop drugs to tackle mental ill-health. Scientists led by the University of Edinburgh analysed data from UK Biobank – a research resource containing health and...
Ubiquigent and Forma Therapeutics have entered into a multi-year strategic research and development (R&D) collaboration agreement for the design and development of novel deubiquitylase (DUB) enzyme inhibitors. Under the terms of the collaboration agreement, Ubiquigent will design novel DUB inhibitors and evaluate them using its biology platform. During this term, Forma will have exclusive access and an option for a worldwide licence to all compounds...
Edinburgh-based pharmaceutical company, Neurocentrx, has appointed two experienced industry professionals to its board. Nigel Brooksby and Dr Tim Corn have joined Neurocentrx as non-executive chairman and non-executive director, respectively, and will take the company to a global market. Neurocentrx is currently developing new clinical indications and new forms of administration for oral ketamine. They want to repurpose an approved human drug most commonly used as...